Zenocutuzumab-zbco

SILVER SPRING, Maryland, May 8, 2026 The U.S. Food and Drug Administration (FDA) has approved Bizengri (zenocutuzumab-zbco) for the...

WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...

LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...